vTv Therapeutics Inc.

vTv Therapeutics is a late-stage biopharmaceutical company developing oral small molecule drug candidates for diabetes and chronic diseases. The company's lead program is cadisegliatin (TTP399), a liver-selective glucokinase activator in Phase III clinical development for type 1 diabetes treatment. Beyond its primary candidate, vTv maintains a pipeline of molecules across various chronic disease indications and holds a license agreement with Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors.

The company operates as a research and development-focused enterprise with limited commercial revenue generation at this stage of development. vTv's business model centers on advancing its clinical pipeline toward regulatory approval and potential commercialization, with dependencies on external funding and partnership agreements to support operations.

Based in High Point, North Carolina, vTv operates with a lean organizational structure of 23 full-time employees. The company was incorporated in Delaware in 2015 and is publicly traded on Nasdaq, reflecting its status as a development-stage biopharmaceutical firm with limited near-term revenue potential.